LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

REVOLUTION Medicines Inc

Închisă

SectorSănătate

38 2.26

Rezumat

Modificarea prețului

24h

Curent

Minim

36.76

Maxim

38.23

Indicatori cheie

By Trading Economics

Venit

-34M

-248M

EPS

-1.13

Marjă de profit

-74.379

Angajați

700

EBITDA

-24M

-261M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+85.52% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-258M

6.7B

Deschiderea anterioară

35.74

Închiderea anterioară

38

Sentimentul știrilor

By Acuity

34%

66%

88 / 372 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 aug. 2025, 22:51 UTC

Câștiguri

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Rev $4.01B

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H Adj EPS $1.84

27 aug. 2025, 23:57 UTC

Câștiguri

Trip.com Group 1H EPS $1.82

27 aug. 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 aug. 2025, 23:39 UTC

Câștiguri

Correction to Nvidia Earnings Article -- WSJ

27 aug. 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 aug. 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 aug. 2025, 22:58 UTC

Câștiguri

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 aug. 2025, 22:57 UTC

Câștiguri

South32 FY Free Cash Flow $192 Million

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Total Capital Expenditure $1.35 Billion

27 aug. 2025, 22:56 UTC

Câștiguri

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 aug. 2025, 22:55 UTC

Câștiguri

South32 Net Cash $123 Million at June 30

27 aug. 2025, 22:54 UTC

Câștiguri

South32: Focused on Maintaining Strong Operating Momentum

27 aug. 2025, 22:53 UTC

Câștiguri

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 aug. 2025, 22:53 UTC

Câștiguri

South32 Extends Capital Management Program for 12 Months

27 aug. 2025, 22:52 UTC

Câștiguri

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 aug. 2025, 22:51 UTC

Câștiguri

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 aug. 2025, 22:50 UTC

Câștiguri

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 aug. 2025, 22:50 UTC

Câștiguri

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 aug. 2025, 22:45 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 aug. 2025, 22:44 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 aug. 2025, 22:43 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 aug. 2025, 22:43 UTC

Câștiguri

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 aug. 2025, 22:42 UTC

Câștiguri

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources Net Debt $123 Million at June 30

27 aug. 2025, 22:40 UTC

Câștiguri

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

85.52% sus

Prognoză pe 12 luni

Medie 69.16 USD  85.52%

Maxim 80 USD

Minim 37.91 USD

În baza a 13 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

13 ratings

13

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

88 / 372 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.